Telmisartan Market Major Players C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd

"Coherent Market Insights announced that it’s published an exclusive report namely Global Telmisartan Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Telmisartan Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry."

Get Latest Insights in Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2524

High prevalence of high blood pressure is expected to aid in growth of the telmisartan market. According to the study, ‘Prevalence of Apparent Treatment-Resistant Hypertension in the United States’, published in the American Heart Association journal Hypertension in February 2019, the prevalence of treatment-resistant hypertension was 17.7% and 19.7% according to the 2008 and 2018 Scientific Statement definitions, respectively, and around 10.3 million adults in the U.S. suffered from treatment-resistant hypertension according to the 2018 Scientific Statement.

Telmisartan, also known as Micardis, is a medicine used to treat high blood pressure (hypertension), heart failure, or diabetic heart disease. This is an effective initial treatment for hypertension. It is taken orally. The drug acts on the autonomic nerves and increases cardiac output by increasing the sympathetic nervous system output. According to the study, ‘Global epidemiology and future trends of heart failure’, published in AME Medical Journal in June 2020, heart failure poses the largest burden after 60 years of age and both prevalence and YLDs have increased by 3.9% and 4.5% in very elderly people during the last 28 years. Such scenario is expected to aid in growth of the telmisartan market.

High prevalence of diabetes also aids in growth of the telmisartan market. According to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Telmisartan affects the release of angiotensinogen, a chemical that increases the blood vessels pressure. In laboratory tests, the drug appears to inhibit the angiotensin II receptor-related mechanism, which regulates the blood pressure from the coronary blood vessels to the peripheral regions. When the drug is given to healthy menopausal women, it appears to normalize blood vessel elasticity and to increase the pressure of the blood from the coronary arteries to peripheral regions, without increasing the blood supply to the extremities. The effects of Telmisartan on angiotensin I-related pathophysiology are still unclear.

Some clinical studies showed that Telmisartan did not reduce the blood pressure when patients took the medication at the same time as antihypertensive medications such as warfarin, atenolol, niacin, or lofexidene. Another study showed that women who were taking warfarin or other antihypertensive medications at the same time as Telmisartan had no significant effects on the blood pressure after four weeks. The drug also showed no significant effect on patients with mild heart failure or on patients with increased bilirubin level in the blood. These results may limit growth of the telmisartan market.

Major Players Are Operating In The Market: C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.

Buy This Research Study Report (Flat US $2000 OFF) @ https://www.coherentmarketinsights.com/promo/buynow/2524

Contact Us

Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.